Tagged with strategy

Global While perhaps not as lucrative or – prior to COVID-19 – as attention-grabbing – as other areas of the pharmaceutical industry, vaccines are also not the forgotten backwaters that many industry insiders seem to view them as. While the inherent complexities related to vaccine R&D do impose high barriers to…

Americas The Top 15 pharmaceutical companies in the Central America and Caribbean (CENCA) market list is dominated by familiar big pharma players. However, among the liked of Sanofi, Abbott, Bayer, Pfizer, AstraZeneca, and Novartis sits Megalabs – a Latin American player that has been able to establish itself as a regional…

Switzerland Dr Chris Martin, CEO and co-founder of Swiss-headquartered antibody-drug conjugate cancer company, ADC Therapeutics, shares the company’s journey over the past decade, the exciting progress of their two lead candidates, the process of building their commercial organization in the US, and his perspectives on Big Pharma partnerships.   We have…

Singapore Bayer’s Dr Vincent Ruland highlights his career trajectory from medical doctor to pharma country manager; the company’s priorities in Malaysia, Singapore, and Brunei; and leveraging the Asian innovation ecosystem.   The industry tends to foster experts and specialists, but the world is changing so rapidly that we need to be…

Taiwan Novo Nordisk’s Steve Profit outlines the progression of the group’s strategy in Taiwan, how the affiliate works with the Taiwanese healthcare system and physicians on diabetes and obesity, the changes that were needed to adapt to the COVID-19 pandemic, and new product launches he is particularly excited about.   Can…

Switzerland CCO Anil Okay introduces how Alvotech’s focus on biosimilars, comprehensive platform, differentiated portfolio approach, and commercial strategy differentiates the company and allows it to compete with the Big Pharma players also present in the biosimilars space.   We position ourselves as a pure play, differentiated, fully vertically integrated biosimilars development…

Switzerland In an exclusive interview, Jean-Paul Clozel explains Idorsia’s unique value proposition as a biotech focused on small molecules, how agnosticism in terms of therapeutic areas leads to more innovative medical breakthroughs, and why scientific innovation continues to motivate him.   When you have started two companies, people think that you…

Switzerland AbbVie Switzerland’s Jon Helsdingen outlines how he has led the Swiss affiliate through a full scale office move, the acquisition and integration of Allergan and the COVID-19 pandemic in a single year. Helsdingen also touches on talent acquisition challenges, the competitive Swiss market, and AbbVie’s digitalisation journey.   We have…

Switzerland Mera Pharma’s Khalid Saleh introduces the Swiss-headquartered but MENA-focused company, how it plans to expand via CMOs, and its evolution from food supplements, cosmetics and medical devices into the more strictly regulated world of pharmaceuticals.   Middle Eastern customers hold Switzerland and its pharmaceutical industry in high esteem. Manufacturing products…

Global In a wide-ranging and exclusive interview with PharmaBoardroom, Ipsen CEO David Loew looks back on an atypical first 100 days at the helm of the iconic French mid-cap; its EUR 3 billion war chest for bolt-on acquisitions; planned expansions in rare- and ultra-rare diseases; and the niche oncology segments where…

Norway Sissel Lønning Andresen explains how Pfizer Norway has been a pioneer of digital communication channels for years, what other Pfizer affiliates can learn from Norway in this field, and how it helped in terms of working through the COVID-19 pandemic. Andresen also highlights her market access priorities, with the gene…

Global DHL’s Larry St Onge outlines how the logistics giant adapted to the COVID-19 pandemic in 2020, the unprecedented cross-industry collaboration that emerged, and the potential for long-term transformation of biopharmaceutical distribution and logistics.   Supply chains will never be the same as they were pre-pandemic. This is now the “new-normal”…